Norditropin (somatropin (rDNA origin) for injection)
Company: Novo Nordisk
Approval Status: Approved February 1997
Treatment for: Growth failure in children
Areas: Endocrinology; Pediatrics/Neonatology
| General Information | Additional Information |
General Information
Norditropin is indicated for the long-term treatment of children who have growth failure due to inadequate secretion of endogenous (pituitary gland produced) growth hormone.
Additional Information
Human growth hormone is responsible for stimulating normal skeletal, connective tissue, muscle and organ growth in children and adolescents. It is also active in normal protein, carbohydrate and fat metabolism. If the amount of growth hormone production by the body is insufficient, short stature, reduced muscle and soft tissue mass and altered nutrient metabolism result. Such problems significantly impact an individual’s physical function throughout life, if not treated appropriately.
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
